The global market for Neuroendocrine Carcinoma was valued at US$ 1291 million in the year 2024 and is projected to reach a revised size of US$ 1868 million by 2031, growing at a CAGR of 5.5% during the forecast period.

Neuroendocrine Carcinoma Market

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

With the continuous advancement of medical technology, more accurate and faster diagnostic methods may be available for the detection of neuroendocrine cancer in the future. This may include more advanced imaging techniques, biomarker testing, and more that can help detect disease earlier and develop treatment options.

This report aims to provide a comprehensive presentation of the global market for Neuroendocrine Carcinoma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuroendocrine Carcinoma.

The Neuroendocrine Carcinoma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuroendocrine Carcinoma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuroendocrine Carcinoma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neuroendocrine Carcinoma Market Report

Report Metric	Details
Report Name	Neuroendocrine Carcinoma Market
Accounted market size in year	US$ 1291 million
Forecasted market size in 2031	US$ 1868 million
CAGR	5.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Chemotherapy Somatostatin Analogs Targeted Therapy
Segment by Application	Hospital Clinics Oncology Centres Ambulatory Surgery Centres
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Novartis, Chiasma, Ipsen, Abbvie, Valeant, Jubilant, Teva, F.Hoffmann-La Roche, Advanced Accelerator, Mateon, Lexicon
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuroendocrine Carcinoma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Neuroendocrine Carcinoma Market growing?

Ans: The Neuroendocrine Carcinoma Market witnessing a CAGR of 5.5% during the forecast period 2025-2031.

What is the Neuroendocrine Carcinoma Market size in 2031?

Ans: The Neuroendocrine Carcinoma Market size in 2031 will be US$ 1868 million.

Who are the main players in the Neuroendocrine Carcinoma Market report?

Ans: The main players in the Neuroendocrine Carcinoma Market are Pfizer, Novartis, Chiasma, Ipsen, Abbvie, Valeant, Jubilant, Teva, F.Hoffmann-La Roche, Advanced Accelerator, Mateon, Lexicon

What are the Application segmentation covered in the Neuroendocrine Carcinoma Market report?

Ans: The Applications covered in the Neuroendocrine Carcinoma Market report are Hospital, Clinics, Oncology Centres, Ambulatory Surgery Centres

What are the Type segmentation covered in the Neuroendocrine Carcinoma Market report?

Ans: The Types covered in the Neuroendocrine Carcinoma Market report are Chemotherapy, Somatostatin Analogs, Targeted Therapy

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Chemotherapy

1.2.3 Somatostatin Analogs

1.2.4 Targeted Therapy

1.3 Market by Application

1.3.1 Global Neuroendocrine Carcinoma Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinics

1.3.4 Oncology Centres

1.3.5 Ambulatory Surgery Centres

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuroendocrine Carcinoma Market Perspective (2020-2031)

2.2 Global Neuroendocrine Carcinoma Growth Trends by Region

2.2.1 Global Neuroendocrine Carcinoma Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Neuroendocrine Carcinoma Historic Market Size by Region (2020-2025)

2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Region (2026-2031)

2.3 Neuroendocrine Carcinoma Market Dynamics

2.3.1 Neuroendocrine Carcinoma Industry Trends

2.3.2 Neuroendocrine Carcinoma Market Drivers

2.3.3 Neuroendocrine Carcinoma Market Challenges

2.3.4 Neuroendocrine Carcinoma Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuroendocrine Carcinoma Players by Revenue

3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2020-2025)

3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2020-2025)

3.2 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Neuroendocrine Carcinoma Revenue

3.4 Global Neuroendocrine Carcinoma Market Concentration Ratio

3.4.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2024

3.5 Global Key Players of Neuroendocrine Carcinoma Head office and Area Served

3.6 Global Key Players of Neuroendocrine Carcinoma, Product and Application

3.7 Global Key Players of Neuroendocrine Carcinoma, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Neuroendocrine Carcinoma Breakdown Data by Type

4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2020-2025)

4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2026-2031)

5 Neuroendocrine Carcinoma Breakdown Data by Application

5.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2020-2025)

5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Neuroendocrine Carcinoma Market Size (2020-2031)

6.2 North America Neuroendocrine Carcinoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Neuroendocrine Carcinoma Market Size by Country (2020-2025)

6.4 North America Neuroendocrine Carcinoma Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuroendocrine Carcinoma Market Size (2020-2031)

7.2 Europe Neuroendocrine Carcinoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Neuroendocrine Carcinoma Market Size by Country (2020-2025)

7.4 Europe Neuroendocrine Carcinoma Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2020-2031)

8.2 Asia-Pacific Neuroendocrine Carcinoma Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2020-2025)

8.4 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neuroendocrine Carcinoma Market Size (2020-2031)

9.2 Latin America Neuroendocrine Carcinoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Neuroendocrine Carcinoma Market Size by Country (2020-2025)

9.4 Latin America Neuroendocrine Carcinoma Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2020-2031)

10.2 Middle East & Africa Neuroendocrine Carcinoma Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2020-2025)

10.4 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuroendocrine Carcinoma Introduction

11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Novartis

11.2.1 Novartis Company Details

11.2.2 Novartis Business Overview

11.2.3 Novartis Neuroendocrine Carcinoma Introduction

11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.2.5 Novartis Recent Development

11.3 Chiasma

11.3.1 Chiasma Company Details

11.3.2 Chiasma Business Overview

11.3.3 Chiasma Neuroendocrine Carcinoma Introduction

11.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.3.5 Chiasma Recent Development

11.4 Ipsen

11.4.1 Ipsen Company Details

11.4.2 Ipsen Business Overview

11.4.3 Ipsen Neuroendocrine Carcinoma Introduction

11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.4.5 Ipsen Recent Development

11.5 Abbvie

11.5.1 Abbvie Company Details

11.5.2 Abbvie Business Overview

11.5.3 Abbvie Neuroendocrine Carcinoma Introduction

11.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.5.5 Abbvie Recent Development

11.6 Valeant

11.6.1 Valeant Company Details

11.6.2 Valeant Business Overview

11.6.3 Valeant Neuroendocrine Carcinoma Introduction

11.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.6.5 Valeant Recent Development

11.7 Jubilant

11.7.1 Jubilant Company Details

11.7.2 Jubilant Business Overview

11.7.3 Jubilant Neuroendocrine Carcinoma Introduction

11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.7.5 Jubilant Recent Development

11.8 Teva

11.8.1 Teva Company Details

11.8.2 Teva Business Overview

11.8.3 Teva Neuroendocrine Carcinoma Introduction

11.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.8.5 Teva Recent Development

11.9 F.Hoffmann-La Roche

11.9.1 F.Hoffmann-La Roche Company Details

11.9.2 F.Hoffmann-La Roche Business Overview

11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction

11.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.9.5 F.Hoffmann-La Roche Recent Development

11.10 Advanced Accelerator

11.10.1 Advanced Accelerator Company Details

11.10.2 Advanced Accelerator Business Overview

11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction

11.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.10.5 Advanced Accelerator Recent Development

11.11 Mateon

11.11.1 Mateon Company Details

11.11.2 Mateon Business Overview

11.11.3 Mateon Neuroendocrine Carcinoma Introduction

11.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.11.5 Mateon Recent Development

11.12 Lexicon

11.12.1 Lexicon Company Details

11.12.2 Lexicon Business Overview

11.12.3 Lexicon Neuroendocrine Carcinoma Introduction

11.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2020-2025)

11.12.5 Lexicon Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Somatostatin Analogs

Table 4. Key Players of Targeted Therapy

Table 5. Global Neuroendocrine Carcinoma Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Neuroendocrine Carcinoma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Neuroendocrine Carcinoma Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Neuroendocrine Carcinoma Market Share by Region (2020-2025)

Table 9. Global Neuroendocrine Carcinoma Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Neuroendocrine Carcinoma Market Share by Region (2026-2031)

Table 11. Neuroendocrine Carcinoma Market Trends

Table 12. Neuroendocrine Carcinoma Market Drivers

Table 13. Neuroendocrine Carcinoma Market Challenges

Table 14. Neuroendocrine Carcinoma Market Restraints

Table 15. Global Neuroendocrine Carcinoma Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Neuroendocrine Carcinoma Market Share by Players (2020-2025)

Table 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2024)

Table 18. Ranking of Global Top Neuroendocrine Carcinoma Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Neuroendocrine Carcinoma, Headquarters and Area Served

Table 21. Global Key Players of Neuroendocrine Carcinoma, Product and Application

Table 22. Global Key Players of Neuroendocrine Carcinoma, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Neuroendocrine Carcinoma Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2020-2025)

Table 26. Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2026-2031)

Table 28. Global Neuroendocrine Carcinoma Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2020-2025)

Table 30. Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2026-2031)

Table 32. North America Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Neuroendocrine Carcinoma Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Neuroendocrine Carcinoma Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Neuroendocrine Carcinoma Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Neuroendocrine Carcinoma Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Neuroendocrine Carcinoma Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Neuroendocrine Carcinoma Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Neuroendocrine Carcinoma Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Neuroendocrine Carcinoma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2026-2031) & (US$ Million)

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer Neuroendocrine Carcinoma Product

Table 50. Pfizer Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Novartis Company Details

Table 53. Novartis Business Overview

Table 54. Novartis Neuroendocrine Carcinoma Product

Table 55. Novartis Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 56. Novartis Recent Development

Table 57. Chiasma Company Details

Table 58. Chiasma Business Overview

Table 59. Chiasma Neuroendocrine Carcinoma Product

Table 60. Chiasma Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 61. Chiasma Recent Development

Table 62. Ipsen Company Details

Table 63. Ipsen Business Overview

Table 64. Ipsen Neuroendocrine Carcinoma Product

Table 65. Ipsen Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 66. Ipsen Recent Development

Table 67. Abbvie Company Details

Table 68. Abbvie Business Overview

Table 69. Abbvie Neuroendocrine Carcinoma Product

Table 70. Abbvie Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 71. Abbvie Recent Development

Table 72. Valeant Company Details

Table 73. Valeant Business Overview

Table 74. Valeant Neuroendocrine Carcinoma Product

Table 75. Valeant Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 76. Valeant Recent Development

Table 77. Jubilant Company Details

Table 78. Jubilant Business Overview

Table 79. Jubilant Neuroendocrine Carcinoma Product

Table 80. Jubilant Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 81. Jubilant Recent Development

Table 82. Teva Company Details

Table 83. Teva Business Overview

Table 84. Teva Neuroendocrine Carcinoma Product

Table 85. Teva Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 86. Teva Recent Development

Table 87. F.Hoffmann-La Roche Company Details

Table 88. F.Hoffmann-La Roche Business Overview

Table 89. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product

Table 90. F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 91. F.Hoffmann-La Roche Recent Development

Table 92. Advanced Accelerator Company Details

Table 93. Advanced Accelerator Business Overview

Table 94. Advanced Accelerator Neuroendocrine Carcinoma Product

Table 95. Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 96. Advanced Accelerator Recent Development

Table 97. Mateon Company Details

Table 98. Mateon Business Overview

Table 99. Mateon Neuroendocrine Carcinoma Product

Table 100. Mateon Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 101. Mateon Recent Development

Table 102. Lexicon Company Details

Table 103. Lexicon Business Overview

Table 104. Lexicon Neuroendocrine Carcinoma Product

Table 105. Lexicon Revenue in Neuroendocrine Carcinoma Business (2020-2025) & (US$ Million)

Table 106. Lexicon Recent Development

Table 107. Research Programs/Design for This Report

Table 108. Key Data Information from Secondary Sources

Table 109. Key Data Information from Primary Sources

Table 110. Authors List of This Report

List of Figures

Figure 1. Neuroendocrine Carcinoma Picture

Figure 2. Global Neuroendocrine Carcinoma Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Neuroendocrine Carcinoma Market Share by Type: 2024 VS 2031

Figure 4. Chemotherapy Features

Figure 5. Somatostatin Analogs Features

Figure 6. Targeted Therapy Features

Figure 7. Global Neuroendocrine Carcinoma Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Neuroendocrine Carcinoma Market Share by Application: 2024 VS 2031

Figure 9. Hospital Case Studies

Figure 10. Clinics Case Studies

Figure 11. Oncology Centres Case Studies

Figure 12. Ambulatory Surgery Centres Case Studies

Figure 13. Neuroendocrine Carcinoma Report Years Considered

Figure 14. Global Neuroendocrine Carcinoma Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Neuroendocrine Carcinoma Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Neuroendocrine Carcinoma Market Share by Region: 2024 VS 2031

Figure 17. Global Neuroendocrine Carcinoma Market Share by Players in 2024

Figure 18. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroendocrine Carcinoma as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2024

Figure 20. North America Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Neuroendocrine Carcinoma Market Share by Country (2020-2031)

Figure 22. United States Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Neuroendocrine Carcinoma Market Share by Country (2020-2031)

Figure 26. Germany Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Neuroendocrine Carcinoma Market Share by Region (2020-2031)

Figure 34. China Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Neuroendocrine Carcinoma Market Share by Country (2020-2031)

Figure 42. Mexico Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2020-2031)

Figure 46. Turkey Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Neuroendocrine Carcinoma Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 50. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 51. Chiasma Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 52. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 53. Abbvie Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 54. Valeant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 55. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 56. Teva Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 57. F.Hoffmann-La Roche Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 58. Advanced Accelerator Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 59. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 60. Lexicon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2020-2025)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Neuroendocrine Tumors NETs Treatment Market Insights Forecast to 2030

Carcinoid Tumor Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Insulinoma Market Research Report 2024

Neuroendocrine Tumor NET Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Brain and Central Nervous System Cancer Treatments Market Research Report 2024

Global Pancreatic Cancer Diagnostic Market Insights Forecast to 2030

Somatostatin Analogue Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pituitary Cancer Market Insights Forecast to 2030

Global Endocrine Testing Market Research Report 2024

Neuroendocrine Carcinoma Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Carcinoid Syndrome Diarrhea Treatment Market Research Report 2024

Neuroendocrine Carcinoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pancreatic Cancer Diagnostic Devices Market Insights Forecast to 2030

Merkel Cell Carcinoma Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Brain Cancer Targeted Drug Market Research Report 2025

Somatostatin Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Primitive Neuroectodermal Tumors PNET Treatment Market Research Report 2024

Global Somatostatin Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031

Global Neuroendocrine Tumor Drug Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions